AUS
NZ
UK
CA
USA
IND
_02_06_2025_07_05_23_538703.jpg)
McKesson Corporation announced that board member James H. Hinton was granted 277 restricted stock units on July 22, 2026, as part of the company’s annual equity compensation program. These units, issued under the 2022 Stock Plan, vest immediately but the actual share delivery is deferred until Hinton leaves the board. This transaction exemplifies McKesson’s ongoing equity incentive strategy for its board members.
Key Points
- NYSE: MCK
- Director James H. Hinton received 277 restricted stock units as part of annual board compensation
- Grant date: July 22, 2026; units vest immediately with deferred share settlement
- Transaction conducted under McKesson’s 2022 Stock Plan compensation framework
Details on Director Equity Award and Vesting Terms
James H. Hinton, serving as a director of McKesson Corporation, received 277 restricted stock units on July 22, 2026. These units carry a zero dollar exercise price, signifying a direct equity award rather than options or warrants. This grant increases Hinton’s beneficial ownership stake in the pharmaceutical and healthcare distribution company.
The units vest immediately, accelerating the economic benefits typically associated with restricted stock. However, the delivery of the underlying common shares is deferred until Hinton’s departure from the board. This vesting and settlement structure aligns with common practices among large-cap healthcare and logistics firms aiming to maintain board continuity while providing meaningful equity exposure to directors.
McKesson’s 2022 Stock Plan Equity Compensation Framework
The restricted stock units were awarded under McKesson’s 2022 Stock Plan as part of the company’s annual equity grant program. This plan is the primary mechanism for delivering equity-based compensation to executives and board members. Utilizing restricted stock units instead of direct stock grants allows McKesson to manage share dilution effectively while offering competitive compensation to its governance team.
Annual grants under this plan represent a standard component of director compensation at major publicly traded healthcare and pharmaceutical distribution companies. By structuring awards through the 2022 Stock Plan, McKesson aligns with shareholder-approved compensation programs and governance best practices. The plan’s design supports retention of qualified directors by providing economic incentives linked to stock performance.
McKesson’s Role and Market Position in Healthcare Distribution
McKesson Corporation is a leading supplier in the pharmaceutical and healthcare supply chain, serving hospitals, pharmacies, physicians’ offices, and other healthcare providers across North America and globally. Its core operations include distributing pharmaceuticals, medical supplies, and healthcare IT solutions to thousands of facilities. This critical infrastructure role places McKesson in a highly regulated and consolidated sector of healthcare services.
McKesson’s business spans pharmaceutical distribution, specialty care solutions, and healthcare information systems. The board oversees strategic decisions impacting the healthcare supply chain that serves millions of patients. Directors like Hinton contribute to governance concerning supply chain resilience, regulatory compliance, and operational efficiency within pharmaceutical and medical product distribution.
Beneficial Ownership and Disclosure Details
Following this grant, Hinton’s beneficial ownership of McKesson common stock includes the 277 shares underlying the restricted stock units. The disclosure confirms direct ownership, indicating Hinton holds these shares personally rather than through a trust or entity. The filing identifies him as a director without officer or ten percent beneficial owner status.
The beneficial ownership figure reflects the cumulative position after the July 22, 2026 award. Securities law treats the deferred settlement arrangement as conferring beneficial ownership of the shares even though actual certificates will be delivered upon board departure. This treatment aligns with Securities Exchange Act interpretations regarding economic interest in securities.
Regulatory Filing and Section 16 Reporting Compliance
The July 23, 2026 filing fulfills McKesson’s obligation under Section 16(a) of the Securities Exchange Act, requiring certain insiders to disclose changes in beneficial ownership. As a Section 16 reporting director, Hinton’s equity grant is a reportable transaction that must be publicly disclosed within two business days. This transparency allows investors to monitor insider equity activities and potential conflicts of interest.
The disclosure follows SEC Form 4 requirements to ensure consistent insider transaction reporting. McKesson and its reporting officers maintain accurate records and file timely updates reflecting ownership changes. These rules promote market transparency regarding insider equity stakes in publicly traded companies.
Board Compensation and Director Incentive Structure
Annual restricted stock unit grants are a key element of McKesson’s director compensation, complemented by cash retainers and meeting fees. Equity awards align directors’ interests with shareholders by providing meaningful stakes in long-term company performance. The deferred settlement feature encourages longer tenure among qualified directors, supporting governance stability.
Healthcare and pharmaceutical distribution firms commonly use equity compensation to attract directors with industry expertise and business acumen. The 277-unit award to Hinton reflects competitive compensation norms at large-cap healthcare companies managing complex supply chains and regulatory environments. Such grants highlight the competitive landscape for experienced directors at major publicly traded corporations.
Grant Execution and Documentation
The restricted stock unit grant was executed on July 22, 2026, with formal disclosure filed on July 23, 2026. The filing was signed by Sarah Ahmad Ali, attorney-in-fact for the reporting person, indicating authorized legal representation in compliance with securities regulations. No amendments to prior filings were noted, confirming this as a standalone grant event.
Documentation specifies the awards were granted under the 2022 Stock Plan’s annual grant program. The zero exercise price confirms these are direct equity grants rather than options or warrants. All material details—including grant date, security type, quantity, and vesting terms—were clearly disclosed in the regulatory filing.
Insider Trading Compliance and Reporting Person Information
James H. Hinton’s address is listed as 6555 North State Highway 161, Irving, Texas, per McKesson’s corporate records. As a Section 16 reporting director, Hinton must disclose all McKesson securities transactions within required timeframes. The filing confirms his director status and notes he does not hold officer or significant beneficial ownership positions triggering additional disclosures.
The disclosure process follows federal securities law procedures for insider transaction reporting. Hinton’s equity grant is a routine, non-discretionary award under an established compensation plan. The immediate vesting combined with deferred settlement reflects McKesson’s approach to equity compensation design and director retention within its governance framework.
Market Context and Investor Insights
Director equity awards are routine compensation activities at publicly traded healthcare and pharmaceutical distribution companies. Hinton’s grant demonstrates McKesson’s ongoing investment in its board and governance infrastructure. Investors tracking insider transactions may view such grants as indicators of management confidence and board stability.
The immediate vesting with deferred settlement suggests confidence in the director’s continued service. The July 22 grant timing aligns with typical annual compensation cycles at large healthcare firms. Public information does not indicate any immediate share price impact from this specific transaction.
